We are live on ! Find out more
OTLK icon

Outlook Therapeutics

68 hedge funds and large institutions have $44.8M invested in Outlook Therapeutics in 2024 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 28 increasing their positions, 10 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,854% more call options, than puts

Call options by funds: $1.64M | Put options by funds: $84K

180% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 10

57% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 7

5% more funds holding

Funds holding: 65 → 68 (+3)

0.86% less ownership

Funds ownership: 36.29% → 35.43% (-0.86%)

6% less capital inflows, than outflows

Capital inflows: $9.06M | Capital outflows: $9.6M

Holders
68
Holders Change
+3
Holders Change %
+4.62%
% of All Funds
0.97%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
28
Reduced
10
Closed
7
Calls
$1.64​M
Puts
$84​K
Net Calls
+$1.56​M
Net Calls Change
+$1.46​M

OTLK Hedge Fund Activity: Q3 2024 in Review

68 of the 6,991 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q3 2024, worth a combined $44.8M — down 29% from $62.7M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new OTLK positions and 7 closed out — a net gain of 4 holders — while 28 added to existing stakes and 10 trimmed.

The largest buyer was BlackRock, adding an estimated $2.79M. The largest seller was Great Point Partners, cutting an estimated $2.99M.

  • 68 institutional investors held Outlook Therapeutics (OTLK) as of Q3 2024, up from 65 in Q2 2024.
  • Funds reported $44.8M of Outlook Therapeutics stock for Q3 2024, down 29% quarter-over-quarter.
  • 11 funds opened new Outlook Therapeutics positions in Q3 2024 and 7 closed out, a net change of +4 holders.
  • The largest Outlook Therapeutics buyer in Q3 2024 was BlackRock, an estimated $2.79M added.
  • The largest Outlook Therapeutics seller in Q3 2024 was Great Point Partners, an estimated $2.99M sold.

Based on aggregated 13F filings for Q3 2024.